Black Diamond Therapeutics (BDTX) Share-based Compensation (2019 - 2026)

Black Diamond Therapeutics (BDTX) has reported Share-based Compensation for 8 consecutive years, with $1.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Share-based Compensation fell 14.97% year-over-year to $1.5 million; the trailing twelve-month figure through Jun 2026 stood at $6.1 million (down 14.02% YoY), and the FY2025 full-year result was $6.6 million, down 37.63% from the prior year.
• Share-based Compensation advanced to $1.5 million in Q2 2026 per BDTX's latest filing, from $1.4 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $5.3 million in Q2 2024 and bottomed at $1.4 million in Q4 2025.
• Historically, Share-based Compensation has averaged $2.3 million across 5 years, with a median of $1.9 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Share-based Compensation soared 99.77% in 2024, then plunged 66.38% in 2025.
• Over 5 years, Share-based Compensation stood at $2.9 million in 2022, then sank by 47.14% to $1.5 million in 2023, then gained by 6.51% to $1.6 million in 2024, then declined by 13.69% to $1.4 million in 2025, then grew by 7.01% to $1.5 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $1.5 million, $1.4 million, and $1.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.